Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
PRNewsWire
·
2026-06-03
·
via The Tech Buzz - Press Releases
Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythema…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。